Patents by Inventor William J. Scott

William J. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080227828
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 18, 2008
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Publication number: 20080194580
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 14, 2008
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20080153823
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: December 13, 2007
    Publication date: June 26, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
  • Patent number: 7371763
    Abstract: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 13, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20080108672
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 8, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Patent number: 7329670
    Abstract: The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the treatment of RAF kinase mediated diseases.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: February 12, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernard Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • Patent number: 7235576
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: June 26, 2007
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Patent number: 6911443
    Abstract: A compound of the formula (I) in which R1 is —OR11, —SR11, —SOR11, —SO2R11, —NHR11, or —NR12R13 , and R11, R12, and R13 are as defined broadly in the text. R2 is H, C1-C6alkyl, carbamoyl, or an ester group. R3 is thienyl, pyridyl optionally substituted by halogen or C1-C6alkoxy; naphthyl optionally substituted by C1-C6alkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: June 28, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Takeshi Yura, Arnel B. Concepcion, Gyoonhee Han, Makiko Marumo, Hiroko Yoshino, Norihiro Kawamura, Toshio Kokubo, Hiroshi Komura, Yingfu Li, Timothy B. Lowinger, Muneto Mogi, Noriyuki Yamamoto, Nagahiro Yoshida, Scott Miller, Margaret A. Popp, Aniko M. Redmann, Martha E. Rodriguez, William J. Scott, Ming Wang
  • Patent number: 6849638
    Abstract: The invention relates to 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same and their use to treat or prevent diseases and conditions mediated by the phosphodiesterase enzyme 7B (PDE7B). Diseases and conditions mediated by PDE7B include osteoporosis, osteopenia and asthma.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: February 1, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Andreas Stolle, Donald E. Bierer, Yuanwei Chen, Dongping Fan, Barry Hart, Mary Katherine Monahan, William J. Scott
  • Publication number: 20040267017
    Abstract: The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.
    Type: Application
    Filed: March 26, 2004
    Publication date: December 30, 2004
    Inventors: Donald E Bierer, Jeffrey Johnson, Gaetan Ladouceur, William J Scott, Andrea C McClure, Wenlang Fu, Furahi Achebe, Michael Burke, Chen Bi, Barry P Hart
  • Publication number: 20040235829
    Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
    Type: Application
    Filed: February 27, 2004
    Publication date: November 25, 2004
    Inventors: William J. Scott, Jacques Dumas, Stephen Boyer, Wendy Lee, Yuanwei Chen, Barton Phillips, Sharad Verma, Jianqing Chen, Zhi Chen, Jianmei Fan, Brian Raudenbush, Aniko Redman, Lin Yi, Qingming Zhu, Lila Adnane
  • Publication number: 20040229937
    Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
    Type: Application
    Filed: March 1, 2004
    Publication date: November 18, 2004
    Inventors: Jacques Dumas, Wendy Lee, Yuanwei Chen, Lila Adnane, William J. Scott, Sharad Verma, Jianqing Chen, Zhi Chen, Lin Yi
  • Patent number: 6784167
    Abstract: 17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 31, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jill E. Wood, Jeremy L. Baryza, Catherine R. Brennan, Soongyu Choi, James H. Cook, Brian R. Dixon, Paul P. Ehrlich, David E. Gunn, Ian McAlexander, Peiying Liu, Derek B. Lowe, Anikó M. Redman, William J. Scott, Yamin Wang
  • Publication number: 20040102636
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 1, 2002
    Publication date: May 27, 2004
    Applicant: BAYER CORPORATION
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20040054179
    Abstract: A compound of the formula (I) wherein R1 is —X—R4, an optionally substituted heterocyclic residue, an optionally substituted carbocyclic residue or optionally substituted condensed ring moiety; X is CR5R6, O, S, SO, SO2 or NR7; Y is CH or N; R2 is H, an optionally substituted C1-C10 alkyl,etc.; R3 is an optionally substituted aryl, or an optionally substituted heteroaryl, etc.; R4 is an optionally substituted aryl, an optionally substituted heteroaryl, etc.; R5, R6, and R7 can be identical or different and represent H, an optionally substituted C1-C10 alkyl, etc. The compound has an excellent anti-allergic activity and the like.
    Type: Application
    Filed: February 14, 2003
    Publication date: March 18, 2004
    Inventors: Takeshi Yura, Arnel b Concepcion, Gyoonhee Han, Makiko Marumo, Hiroko Yoshino, Norihiro Kawamura, Toshio Kokubo, Hiroshi Komura, Yingfu Li, Timothy B LOwinger, Muneto Mogi, Noriyuki Yamamoto, Nagahiro Yoshida, Scott Miller, Margaret A Popp, Aniko M Redmann, Martha E Rodriguez, William J Scott, Ming Wang
  • Publication number: 20040023961
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: February 11, 2003
    Publication date: February 5, 2004
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Publication number: 20030216396
    Abstract: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Application
    Filed: February 11, 2003
    Publication date: November 20, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, William J. Scott, Bernd Riedl
  • Publication number: 20030216446
    Abstract: This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Application
    Filed: February 11, 2003
    Publication date: November 20, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, William J. Scott, Bernd Riedl, Du-Shieng Chien, Ala Nassar, Wendy Lee, Susan Bjorge, Laszlo L. Musza
  • Publication number: 20030207872
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: January 11, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Publication number: 20030207914
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood